Ensysce Biosciences, Inc. (ENSC) - 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Ensysce Biosciences, Inc. is a clinical-stage biotechnology company focused on developing abuse-resistant and overdose-protective opioid therapies. The company's lead product candidate, PF614 (an extended-release oxycodone prodrug), is in Phase 3 clinical development. The company has not generated any product revenue and relies on federal grants and equity/debt financing to fund operations.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue (Federal Grants) | $2,125,313 | $2,691,210 |
| Net Loss | $(6,127,290) | $(3,679,090) |
| Net Loss Per Share (Basic & Diluted) | $(0.62) | $(2.04) |
| Cash and Cash Equivalents (End of Period) | $676,704 | $2,211,575 |
| Total Assets | $2,957,273 | $7,452,479 |
| Total Liabilities | $4,068,106 | $4,567,729 |
| Stockholders' Equity (Deficit) | $(1,110,833) | $2,884,750 |
| Net Cash Used in Operating Activities | $(5,463,383) | $(4,414,280) |
| Net Cash Provided by Financing Activities | $1,829,733 | $3,123,778 |
Debt and Liquidity: As of June 30, 2026, the company held $196,842 in notes payable (financed insurance premiums). The 2023 convertible notes were converted to equity in April 2026. The company reported a negative working capital position, with current liabilities of $4.1 million exceeding current assets of $2.8 million.
Material Changes vs. Prior Period
- Revenue Decline: Federal grant revenue decreased by approximately $0.6 million (21%) compared to the prior year period, attributed to the timing of research activities eligible for funding under the MPAR grant.
- Increased Operating Expenses: Total operating expenses rose by $1.9 million to $8.3 million. Research and Development (R&D) expenses increased by $2.0 million to $5.8 million, driven by increased clinical activity for the PF614 Phase 3 trial. General and Administrative (G&A) expenses decreased slightly by $0.2 million.
- Equity Dilution and Financing: The company completed a private placement in April 2026, issuing 2,000 shares of Series B Preferred Stock for $2.0 million in gross proceeds. Additionally, 2023 convertible notes were converted into 508,614 shares of common stock and warrants.
- Cash Burn: Cash and cash equivalents decreased by $3.6 million during the six-month period, leaving the company with approximately $0.7 million in cash at quarter-end.
Outlook, Risks, and Unusual Items
- Going Concern Warning: The filing explicitly states that the company's ability to continue as a going concern for the next twelve months is in substantial doubt. Management estimates current cash resources are sufficient only through the late third quarter of 2026 without additional financing.
- Subsequent Event - Acquisition: On August 5, 2026, Ensysce completed the acquisition of Cy Biopharma, Inc., a clinical-stage biotech focused on chronic pain therapies. Concurrently, the company secured approximately $21.5 million in private placement financing, with potential for an additional $38.6 million upon milestone achievement.
- Commitments: The company has open purchase orders and contractual obligations totaling approximately $15.6 million, primarily related to clinical research studies funded by federal grants.
- Risk Factors: Key risks include the potential delisting from Nasdaq if listing standards are not met, the failure of clinical trials (specifically PF614 and PF614-MPAR), and the inability to secure necessary capital to fund operations.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $21.5 million raised in the August 2026 financing to cover the $15.6 million in committed obligations and ongoing operational burn rates.
- Grant Funding Status: Confirm the remaining $5.3 million in MPAR grant funding and the timeline for utilization through May 2027.
- Acquisition Integration: Review the preliminary purchase price allocation and financial impact of the Cy Biopharma acquisition once finalized.
- Preferred Stock Terms: Analyze the liquidation preferences and conversion terms of the Series B and Series C Preferred Stock, which may significantly impact common equity value in a liquidation or exit scenario.
- Clinical Trial Progress: Monitor the status of the Phase 3 trial for PF614, as delays or failures would materially impact the need for further capital and the company's valuation.